HitGen(SH:688222)2026-01-28 02:00Summary of the Conference Call Record Company Overview - The document pertains to Guoxin Pharmaceutical (国信医药), specifically regarding its performance forecast for the year 2025. Key Points and Arguments 1. Projected Financial Performance: - The company expects to achieve a net profit attributable to shareholders of CNY 1.04 to 1.27 billion, representing a growth of 102.50% to 147.29% compared to the previous year's profit of CNY 0.51 billion [1] - The non-recurring net profit is projected to be CNY 1.06 to 1.29 billion, reflecting an increase of 84.55% to 124.59% from last year's CNY 0.57 billion [1] 2. Core Business Growth: - The DEL (DNA-Encoded Library) business is experiencing steady growth with a high gross margin, contributing significantly to profit enhancement [2] - The UK subsidiary Vernalis is also seeing stable growth in its FBDD/SBDD (Fragment-Based Drug Discovery/Structure-Based Drug Discovery) platform, with milestone revenues achieved from client projects [2] 3. New Business Segment Development: - The OBT (Oligonucleotide-Based Therapeutics) segment is expanding its traditional business while leveraging delivery molecule-related services to achieve commercial transformation of small nucleic acid projects, showing significant year-on-year revenue growth [2] - The ChemSer segment's revenue has also increased year-on-year due to the high operational efficiency of the automated high-throughput chemical synthesis platform [2] 4. Reduction in Fair Value Change Losses: - The company anticipates a decrease in fair value change losses for 2025, primarily due to reduced impacts from changes in the fair value of trading financial liabilities [2]